Bharat Biotech working on Nasal Vaccine as Booster Dose: Reports

Managing Director Krishna Ella said that apart from Covaxin, the company has also developed BBV154, an intragenal vaccine against covid-19.

Yogita S.

Yogita S.By Yogita S.

Published on 16 Aug 2021 11:29 AM GMT

Bharat Biotech working on Nasal Vaccine as Booster Dose: Reports
X

Intranasal Vaccine (PC: Social Media)

  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Print
  • koo
  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Print
  • koo
  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Print
  • koo

New Delhi: Talking about Bharat Biotech's contribution and efforts in relation to vaccination, Managing Director Krishna Ella said that apart from Covaxin, the company has also developed BBV154, an intragenal vaccine against covid-19.

Ella said, "After the nasal vaccine, we are working on a combination of covaxin, so that the covaxin can produce three immune responses."

Nasal Vaccine as Booster Dose:

Ella told that all three immunities are powerful and can protect against getting infected. "We may have a lot of data in the next two months. So, we are not only working on this, but also on a booster dose of the vaccine," Dr Ella said.

When asked what would be the need of a third dose to increase the immune response for a long time, Dr Ella replied in the affirmative and said, "Yes, we will give the data to the government, it is for the government to decide with the regulatory agencies. If the nasal vaccine is okay." Our production capacity will be doubled and we are expecting that."

Bharat Biotech is currently supplying around 20-25 million doses of Covaxin per month, which is expected to increase to about 580 million doses in the next few months. The Department of Biotechnology said on Friday that Bharat Biotech's first nasal vaccine developed against covid-19 has received regulatory approval for Phase II human trials.

Bharat Biotech Vaccine:

"Bharat Biotech's intranasal vaccine BBV154 has become the first nasal vaccine to receive regulatory approval for Phase II human trials," DBT said in a statement.

According to him, the first phase of human trials has been completed on the age group of 18 to 60 years. The development of Bharat Biotech's intranasal vaccine has been supported by the Department of Biotechnology and the Biotechnology Industry Research Assistance Council.

Dr. Renu Swarup, Secretary, DBT said, "The department is dedicated to the development of safe and effective COVID-19 under the COVID Suraksha Mission. Bharat Biotech's BBV154 vaccine is the first intranasal vaccine entering the final stage of human trials."

Stay tuned with the newstrack to get fastest updates. Click @englishnewstrack to follow us on Facebook and @newstrackmedia to follow on Twitter.

Yogita S.

Yogita S.

She covers current News topics, keeps the audience updated with Buzz around the world. Also a PR Enthusiast.

Next Story